Table 2.

Risk of Sjogren’s syndrome in patients with psoriasis compared to non-psoriasis individuals

	N	Follow-up time (person-years)	No. of SS	Cumulative incidence (%)	Incidence rate (cases/1000 person-years)	HR (95% C.I.)
Model 1
Non-psoriasis	293,905	1,591,701	1659	2.54	1.04	Reference
Psoriasis	293,905	1,832,753	3339	3.32	1.82	1.76 (1.66–1.87)
Model 2
Non-psoriasis	293,905	1,590,991	1825	2.65	1.15	Reference
Psoriasis	293,905	1,832,753	3339	3.32	1.82	1.60 (1.51–1.69)
Model 3
Non-psoriasis	293,905	1,580,527	1937	2.88	1.23	Reference
Psoriasis	293,905	1,832,753	3339	3.32	1.82	1.50 (1.42–1.58)
Group
Psoriasis without PsA	72,242	450,869	623	2.79	1.38	Reference
Psoriatic arthritis	72,242	419,248	1319	4.66	3.15	2.27 (2.06–2.49)
Group
Psoriasis without biological agents	30,819	185,177	325	2.90	1.76	Reference
Psoriasis with biological agents	30,819	165,402	488	4.79	2.95	1.66 (1.44–1.91)

BMI body mass index, PsA psoriatic arthritis, SS Sjogren’s syndrome, HR hazard ratio, CI confidence interval

Model 1: Propensity matching by age, sex, race, socioeconomic status, BMI, and medical utilization

Model 2: Propensity matching by age, sex, race, socioeconomic status, BMI, medical utilization, and comorbidities

Model 3: Propensity matching by age, sex, race, socioeconomic status, BMI, medical utilization, comorbidities, and medication